journal

OCALA, Fla., June 27, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its TLR-3 agonist Ampligen (rintatolimod) as a novel…

MINNEAPOLIS, June 22, 2023 (GLOBE NEWSWIRE) -- Results of a Phase III randomized clinical trial published in the New England Journal of Medicine indicates that a new strategy for prevention of graft versus host disease (GVHD) for blood…

PAD, characterized by vascular inflammation and associated calcification, affects 8.5 million people in the United States and contributes to more than 50,000 limb amputations annually, yet there are no specific pharmacologic…

TUCSON, Ariz., June 19, 2023 (GLOBE NEWSWIRE) -- In recent decades, hospitals have increasingly merged and acquired physician practices. “In the quest to create larger and more robust monopolies, some hospitals are using sham peer review…

TUCSON, Ariz., June 19, 2023 (GLOBE NEWSWIRE) -- The controversial 2022 video Died Suddenly has sparked devastating criticisms from both COVID vaccine proponents and skeptics, but the question remains: Are the vaccines a potential cause…

TUCSON, Ariz., June 19, 2023 (GLOBE NEWSWIRE) -- A number of hospitals have been sued for refusing to allow patients dying of COVID to receive treatment with ivermectin. If the hospital lost, it appealed the decision, even if the patient…

TUCSON, Ariz., June 19, 2023 (GLOBE NEWSWIRE) -- Licensure boards are supposed to protect the public from dangerous practitioners. But while often failing in this basic function, they frequently abuse their power, writes Sheila Page,…

© Reuters. FILE PHOTO: Billionaire investor George Soros speaks to the audience at the Schumpeter Award in Vienna, Austria June 21, 2019. REUTERS/Lisi Niesner (Reuters) - Billionaire financier George Soros told the Wall Street Journal…

SAN DIEGO, June 09, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced the publication of results of its Phase 1/2 clinical study of DARE-VVA1, a proprietary,…

GUANGZHOU, China, June 08, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) is pleased to announce that our flagship comprehensive genomic profiling (CGP) product,…